ACTU vs ALNY · $49.0M cap vs P/E 76, rev $1.29B
Actuate Therapeutics, Inc. Common stock (ACTU) versus Alnylam Pharmaceuticals Inc (ALNY) — a side-by-side from cached financials, not a winner call.
Actuate Therapeutics, Inc. Common stock (ACTU) is a biotechnology company listed on NASDAQ.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
ACTU does not have a complete income-statement cache yet.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
ACTU currently screens at market cap $49.0M. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Not investment advice. Open the ACTU and ALNY stock pages for the full models.
Not investment advice.